ZGNX News and Press, Zogenix Inc. From 07/14/21

EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP Siblings , a new website and suite of materials created to celebrate and ...

Zogenix launched its first product, Fintepla, last July and has since beaten analyst expectations in every quarter. Despite that and having a large cash balance, Zogenix stock has remained depressed since the launch. Personally, I initiated a position recently and intend to hold l...

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming investor conferences: the Raymond...

Maksim Labkouski/iStock via Getty Images Zogenix (ZGNX) rose 3.6% after speculation that the company could potentially attract an activist. Zogenix could be an activist target as it shares have underperformed peers, the stock appears cheap and it has had occasional activists showing sign...

EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive V...

Zogenix, Inc. (ZGNX) Q1 2021 Earnings Conference Call May 6, 2021 16:30 ET Company Participants Brian Ritchie - LifeSci Advisors Stephen Farr - Co-Founder, Chief Executive Officer, President & Director Ashish Sagrolikar - Executive Vice President & Chief Commercial Officer Michael Smi...

Zogenix (ZGNX): Q1 GAAP EPS of -$1.00 beats by $0.02.Revenue of $13.68M (+994.4% Y/Y) beats by $1.34M.As of March 31, 2021, the Company had $435.2 million in cash, cash equivalents, and marketable securities, compared to $505.1 million at December 31, 2020.Press Release For further details ...

Continued positive momentum for U.S. launch of FINTEPLA ® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $12.3 million and total revenue of $13.7 million in the first quarter, representing quarter-over-quarter increases o...

FINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with Dravet syndrome in patients aged two years and older. The new program supports physician access to FINTEPLA in other parts of the world, where local regulatio...

Zogenix (ZGNX) announces new data showing the positive impact of treatment with Fintepla (fenfluramine) oral solution on everyday executive function for children and young adults with Lennox-Gastaut syndrome ((LGS)), a rare, severe epilepsy. Treatment continued for a combined 14-week titratio...